Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cellectar Biosciences ( (CLRB) ) just unveiled an update.
On June 5, 2025, Cellectar Biosciences entered into agreements to raise $2.5 million through the sale of common stock, with the closing expected around June 6, 2025. This transaction involves the immediate exercise of outstanding warrants for 8,301,322 shares at a reduced price, with proceeds intended for general corporate purposes.
The most recent analyst rating on (CLRB) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Cellectar Biosciences stock, see the CLRB Stock Forecast page.
Spark’s Take on CLRB Stock
According to Spark, TipRanks’ AI Analyst, CLRB is a Underperform.
Cellectar Biosciences faces significant financial challenges with no revenue generation and heavy reliance on external financing. Technical indicators suggest a bearish trend, and the company’s valuation is weakened by negative earnings. Although the earnings call highlighted some clinical and regulatory progress, these are overshadowed by financial and operational setbacks, leading to a below-average overall stock score.
To see Spark’s full report on CLRB stock, click here.
More about Cellectar Biosciences
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for cancer treatment. The company leverages its Phospholipid Drug Conjugate™ (PDC) delivery platform to develop targeted cancer therapies, including iopofosine I 131, CLR 121225, and CLR 121125, among others.
Average Trading Volume: 10,906,691
Technical Sentiment Signal: Sell
Current Market Cap: $12.79M
See more data about CLRB stock on TipRanks’ Stock Analysis page.